Type 1 Diabetes – Landscape & Forecast – Disease Landscape & Forecast (G7)
The treatment options for type 1 diabetes (T1D) patients are limited; insulins, pramlintide (in the United States), and sodium-glucose cotransporter-2 (SGLT-2) inhibitors (only in Japan) are the only approved therapies. The launch of Sanofi / Provention Bio’s novel disease-modifying therapy teplizumab (Tzield) and Novo Nordisk’s first-in-class weekly insulin icodec (Awiqli) represents significant advancements in the T1D market. There is a substantial unmet need for disease-modifying therapies that could enhance the long-term outcomes for T1D patients. Emerging therapies, such as pancreatic beta-cell replacement therapies and CD3 antigen inhibitors, are being investigated for their potential effectiveness in newly diagnosed patients, aiming to slow the progression of T1D.
QUESTIONS ANSWERED
- What are the drivers and constraints in the T1D market and how will the market evolve over the forecast period?
- What impact will the launch of Novo Nordisk’s insulin icodec (Awiqli) have on daily basal insulins and the overall use of insulin analogues?
- What is the impact of the launch of Sanofi / Provention Bio’s teplizumab (Tzield) on insulins and the overall approach to managing T1D?
- How are biosimilar insulins being adopted and how will they impact the overall T1D market?
- What changes will the increasing use of insulin pumps bring to market dynamics?
CONTENT HIGHLIGHTS
- Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
- Primary research: Country-specific interviews with thought-leading endocrinologists and diabetologists. Survey data collected for this and other Clarivate research.
- Epidemiology: Diagnosed prevalence of T1D by country and drug-treated rates.
- Forecast: 10-year, annualized, drug-level sales and patient share of T1D therapies through 2034, segmented by brands / generics and subpopulations.
- Drug treatments: Coverage of key current and late-phase emerging therapies.
PRODUCT DESCRIPTION
Disease Landscape & Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:
- Optimize your long-term disease and development strategy.
- Quantify market potential for your pipeline assets and those of your competitors.
- Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.
- Gauge the commercial outlook and impact of key market events.
Table of contents
- Type 1 Diabetes - Landscape & Forecast - Disease Landscape & Forecast (G7)
